How Accurate Are Clinical Trial Publications?

An analysis of 164 phase III breast cancer trials shows bias in reporting the primary endpoint and toxicity results, according to results of a recent study.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news

Related Links:

Publication date: Available online 21 November 2019Source: Biochimica et Biophysica Acta (BBA) - Molecular Cell ResearchAuthor(s): Neha Upmanyu, Ahmed Bulldan, Klaus Failing, Georgios Scheiner-BobisAbstractIt is generally assumed that circulating dehydroepiandrosterone sulfate (DHEAS) can be desulfated and further metabolized to estrogen, which is of concern for all patients with estrogen-responsive breast cancer. We addressed this issue by comparing the effects of DHEAS, its desulfated form DHEA, and 17ß-estradiol on human metastatic, estrogen-responsive MCF-7 breast cancer cells.Physiological concentrations of DHEA...
Source: Biochimica et Biophysica Acta (BBA) Molecular Cell Research - Category: Molecular Biology Source Type: research
Publication date: Available online 20 November 2019Source: Redox BiologyAuthor(s): Lin Yang, Zihao He, Jingyue Yao, Renxiang Tan, Yejin Zhu, Zhiyu Li, Qinglong Guo, Libin Wei
Source: Redox Biology - Category: Biology Source Type: research
This study, therefore, investigated the potential of two depsidones (Unguinol and Aspergillusidone D) to induce apoptosis, cell cycle arrest and cytotoxicity, and reduce cell proliferation in the triple-negative MDA-MB-231 breast cancer cell line. Results were compared with the effects of the cytostatic drug doxorubicin, antimitotic agent colchicine and endogenous hormones 17β-estradiol, testosterone and dihydrotestosterone.The cytostatic drugs and hormones affected the MDA-MB-231 cell line comparable to other studies, showing the usefulness of this model to study the effects of depsidones on a triple-negative breast ...
Source: Toxicology Reports - Category: Toxicology Source Type: research
We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Monday, 16 December 2019, highlighting Roche data presented at the San Antonio Breast Cancer Symposium in San Antonio, Texas, from 10th - 14th December.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
This study identified correlates of good screening performance for three common cancers, while weighing them against the backdrop of existing knowledge, to enable policy makers and healthcare providers focus appropriately to close the gaps that exist in cancer screening in our locale. Study design: Cross-sectional design. Setting: Tertiary health facility. Participants: Workers at Delta State University Teaching Hospital, Nigeria. Results: Females had significantly better knowledge of cervical cancer, p
Source: Ghana Medical Journal - Category: African Health Tags: Ghana Med J Source Type: research
(University of Illinois at Chicago) $1.8 million in funding will help young breast cancer survivors navigate post-treatment care and survival.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
(Universitat Autonoma de Barcelona) Researchers from the CIBER-BBN and the Universitat Aut ò noma de Barcelona use bioengineering to design non-toxic drug-release granules to be administered locally and with prolonged therapeutic effects.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Oncotype DX ® Breast Recurrence Scores from the National Cancer Database indicated that a lower threshold is needed for male patients with early stage ER-positive breast cancer to predict mortality.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
T, Saarto T Abstract Background: To avoid aggressive treatments at the end-of-life and to provide palliative care (PC), physicians need to terminate futile anti-cancer treatments and define the palliative goal of the treatment in time. This single center study assesses the practices used to make the decision that leads to treatment with a palliative goal, i.e., the PC decision and its effect on anti-cancer treatments at the end of life.Material and methods: Patients with a cancer diagnosis treated in tertiary hospital during 1st January 2013 - 31st December 2014 and deceased by the end of 2014 were identified in t...
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
This article presents recent data informing these contemporary developments in the radiotherapeutic management of breast cancer. PMID: 31739937 [PubMed - in process]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Hematol Oncol Clin North Am Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | Study | Toxicology